Understanding Clinical Trial Experiences for Squamous Cell Carcinoma
This observational study is looking to understand why some people with squamous cell carcinoma (a type of skin cancer) join clinical trials and why some complete them. There are no specific treatments or interventions being tested in this study. Instead, researchers want to gather information from 500 participants about their experiences with clinical trials. The study aims to identify what helps or hinders people from enrolling in and finishing a trial. To be eligible, you must be at least 18 years old with a confirmed diagnosis of squamous cell carcinoma and be able to follow the study's instructions. The study will measure how many patients decide to enroll in a trial after 3 months and how many stay in a trial until it's finished after 12 months. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 500 participants to gather information about their experiences with clinical trials.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track enrollment decisions at 3 months and trial completion rates at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael B Gill · STUDY_DIRECTOR · Power Life Sciences Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of patients who decide to enroll in a squamous cell carcinoma clinical trial3 months
- Rate of patients who remain in squamous cell carcinoma clinical trial to trial completion12 months